Piper Sandler Companies

Piper Sandler Companies is an American multinational investment bank and financial services company, founded in 1895 and headquartered in Minneapolis, Minnesota. The firm's mission is to help clients "Realize the Power of Partnership®" by providing deep sector expertise and candid advice.

The company offers a comprehensive suite of products and services, including mergers and acquisitions advisory, financial restructuring, public offerings, public finance, institutional brokerage, investment management, and securities research. It provides advisory and financing services related to equity and debt capital markets, private placements, and restructuring transactions. Piper Sandler serves a diverse client base, including corporations, institutional investors, public entities, private equity groups, and non-profit entities across various sectors such as healthcare, energy, consumer, technology, and financial services.

Led by Chairman and CEO Chad R. Abraham and President Deb Schoneman, Piper Sandler Companies completed its merger with Sandler O'Neill + Partners in January 2020, forming the current entity. The firm reported strong first-quarter 2026 results, achieving a 22% year-over-year revenue growth driven by corporate investment banking, and increased its quarterly dividend to $0.20 per share. Piper Sandler maintains a strong market position as a leading investment bank, particularly noted for its robust healthcare franchise.

Latest updates

Piper Sandler Boosts Dividend Amidst Q1 Earnings Release

Event summary

  • Piper Sandler Companies (PIPR) released its Q1 2026 financial results.
  • The complete earnings release is available on the company's website.
  • An earnings conference call is scheduled for May 1, 2026, at 7:30 AM CT.
  • The company increased its quarterly dividend to $0.20 per share.

The big picture

Piper Sandler's dividend increase signals confidence in the firm's financial health and future prospects. However, the investment banking landscape remains sensitive to macroeconomic conditions and regulatory changes. The firm's performance will be a key indicator of the broader health of the M&A market and the resilience of regional investment banks.

What we're watching

Profitability
The Q1 results will reveal whether the firm's investment banking activity has recovered from recent market volatility, and how this impacts overall profitability.
Regulatory Scrutiny
Increased regulatory oversight in the financial sector, particularly concerning investment banking practices, may constrain future growth and profitability.
Deal Flow
The pace at which deal flow returns to pre-pandemic levels will significantly influence Piper Sandler's revenue generation and ability to sustain the increased dividend.

Piper Sandler Bolsters Biopharma Banking with Ex-Wells Fargo Hire

Event summary

  • Piper Sandler hired Patrick McCormack, M.D., as a managing director in its healthcare investment banking group.
  • McCormack will be based in San Francisco and focus on biopharma M&A and capital raising.
  • Prior to Piper Sandler, McCormack held executive director roles at Wells Fargo Securities and previously held senior positions at Goldman Sachs, SVB Leerink, and SunTrust Robinson Humphrey.
  • McCormack brings a medical and business background, holding an M.D. and an MBA.

The big picture

Piper Sandler’s move signals an intensified competition for biopharma investment banking talent, as firms seek to capitalize on the sector’s ongoing M&A activity and capital-raising needs. The addition of a physician with McCormack’s experience suggests a strategic focus on providing specialized advisory services to biopharma companies navigating complex regulatory and scientific landscapes. This hire is part of a broader trend of investment banks seeking to deepen their expertise in specialized sectors to gain a competitive edge.

What we're watching

Deal Flow
McCormack’s experience may accelerate Piper Sandler’s deal flow in the biopharma sector, particularly given the ongoing consolidation within the industry.
Client Migration
The extent to which McCormack’s existing client relationships follow him to Piper Sandler will be a key indicator of the hire’s immediate impact.
Competitive Landscape
Piper Sandler’s ability to retain and win biopharma clients will depend on its capacity to offer differentiated services against competitors like Goldman Sachs and SVB Leerink.
CID: 3085